Low-dose aspirin and survival from lung cancer: A population-based cohort study

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Mc Menamin, Úna C ^a   Cardwell, Chris R ^a   Hughes, Carmel M ^a   Murray, Liam M ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

CPRD; Low dose aspirin; Lung cancer survival; Pharmacoepidemiology

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR;

ADULT; AGED; ARTICLE; BODY MASS; CANCER MORTALITY; CANCER REGISTRY; CANCER SURVIVAL; COHORT ANALYSIS; FEMALE; HUMAN; LOW DRUG DOSE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; RISK REDUCTION; SMALL CELL LUNG CANCER; SMOKING; UNITED KINGDOM; VERY ELDERLY; CASE CONTROL STUDY; EPIDEMIOLOGY; LUNG NEOPLASMS; MIDDLE AGED; MORTALITY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ASPIRIN; CASE-CONTROL STUDIES; COHORT STUDIES; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; UNITED KINGDOM;

EID: 84959125251     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1910-9     Document Type: Article

References (37)

1. Gasic GJ, Gasic TB, Stewart CC. Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci. 1968;61(1):46-52.
2. Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost. 2011;9(2):237-49.
3. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011;11(2):123-34.
4. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med. 2012;367(17):1596-606.
5. Ng K, Meyerhardt JA, Chan AT, Sato K, Chan JA, Niedzwiecki D, et al. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer. J Natl Cancer Inst. 2015;107(1):345.
6. Kwan ML, Habel LA, Slattery ML, Caan B. NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control. 2012;46(13):2473-8.
7. Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. J Clin Oncol. 2010;28(9):1467-72.
8. Choe KS, Cowan JE, Chan JM, Carroll PR, D'Amico AV, Liauw SL. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol. 2012;30(28):3540-4.
9. Langley RE, Wilson RH, Ring A, Kynaston HG, Murphy CM, Cameron DA, et al. Evidence for the use of aspirin as a treatment for cancer and the planned Add-Aspirin trial. Berlin, Germany: The First World Congress on Controversies in Gastroenterology; 2013. Available from: http://www.comtecmed.com/cigi/2013/Abstracts_Text.aspx. Accessed January 2015.
10. United States National Institutes of Health: Study record detail: the effect of aspirin on survival in lung cancer: study record detail. Available from: https://clinicaltrials.gov/ct2/show/NCT01058902. Accessed January 2015.
11. Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G. Aspirin, salicylates, and cancer. Lancet. 2009;373(9671):1301-9.
12. Langley RE, Burdett S, Tierney JF, Cafferty F, Parmar MKB, Venning G. Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? Br J Cancer. 2011;105(8):1107-13.
13. Din FVN, Valanciute A, Houde VP, Zibrova D, Green K, Sakamoto K, et al. Aspirin inhibits mTOR signaling, activates AMP-activated protein kinase, and induces autophagy in colorectal cancer cells. Gastroenterology. 2012;142(7):1504-15.
14. Borthwick GM, Johnson AS, Partington M, Burn J, Wilson R, Arthur HM. Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism. FASEB J. 2006;20(12):2009-16.
15. Lloyd Jr FP, Slivova V, Valachovicova TSD. Aspirin inhibits highly invasive prostate cancer cells. Int J Oncol. 2003;23(5):1277-83.
16. Mezouar S, Darbousset R, Dignat-George F, Panicot-Dubois L, Dubois C. Inhibition of platelet activation prevents the P-selectin and integrin-dependent accumulation of cancer cell microparticles and reduces tumor growth and metastasis in vivo. Int J Cancer. 2015;136(2):462-75.
17. Duperron C, Castonguay A. Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Carcinogenesis. 1997;18(5):1001-6.
18. Ogawa F, Amano H, Ito Y, Matsui Y, Hosono K, Kitasato H, et al. Aspirin reduces lung cancer metastasis to regional lymph nodes. Biomed Pharmacother. 2014;68(1):79-86.
19. Jonsson F, Yin L, Lundholm C, Smedby KE, Czene K, Pawitan Y. Low-dose aspirin use and cancer characteristics: a population-based cohort study. Br J Cancer. 2013;109(7):1921-5.
20. Wang H, Liao Z, Zhuang Y, Liu Y, Levy LB, Xu T, et al. Incidental receipt of cardiac medications and survival outcomes among patients with stage III non-small-cell lung cancer after definitive radiotherapy. Clin Lung Cancer. 2014. doi: 10.1016/j.cllc.2014.09.006.
21. Fontaine E, McShane J, Page R, Shackcloth M, Mediratta N, Carr M, et al. Aspirin and non-small cell lung cancer resections: effect on long-term survival. Eur J Cardiothorac Surg. 2010;38(1):21-6.
22. Lebeau B, Chastang MDMJ. No effect of an antiaggregant treatment with aspirin in small cell lung cancer treated with CCAVPI 6 chemotherapy. Cancer. 1992;71(5):1741-5.
23. Jick H, LE Jick SSD. Validation of information recorded on general practitioner based computerised data resource in the United Kingdom. Br Med J. 1991;302:766-8.
24. Boggon R, Van Staa TP, Chapman M, Gallagher AM, Hammad TA, Richards MA. Cancer recording and mortality in the General Practice Research Database and linked cancer registries. Pharmacoepidemiol Drug Saf. 2013;22:168-75.
25. British medical association and the royal pharmaceutical society of great Britain: British national formulary. Available from: http://www.bnf.org/products/bnf-online/. Accessed January 2015.
26. Khan NF, Perera R, Harper S, Rose PW. Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam Pract. 2010;11:1.
27. Noble M, Wright G, Dibben C, Smith GAN, McLennan D, Anttila C, et al. Indices of deprivation 2004: Report to the office of the deputy prime minister. London, UK: Neighb Renew Unit; 2004.
28. Chubak J, Boudreau DM, Wirtz HS, McKnight B, Weiss NS. Threats to validity of nonrandomized studies of postdiagnosis exposures on cancer recurrence and survival. J Natl Cancer Inst. 2013;105(19):1456-62.
29. Tamim H, Monfared AAT, Lelorier J. Application of lag time into exposure definitions to control for protopathic bias. Pharmacoepidemiol Drug Saf. 2007;16:250-8.
30. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf. 2007;16:241-9.
31. Weinberg CR. Toward a clearer definition of confounding. Am J Epidemiol. 1993;137(1):1-3.
32. Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary adjustment in epidemiologic studies. Epidemiology. 2009;20(4):488-95.
33. Rothwell PM, Fowkes FGR, Belch JFF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet. 2011;377(9759):31-41.
34. Brasky TM, Baik CS, Slatore CG, Alvarado M, White E. Pre-diagnostic non-steroidal anti-inflammatory drug use and cancer survival in the VITAL study. J Thorac Oncol. 2012;7:1503-12.
35. Sarfati D, Blakely T, Pearce N. Measuring cancer survival in populations: relative survival vs cancer-specific survival. Int J Epidemiol. 2010;39(2):598-610.
36. Yang Y, Pharmd SH, Propert K, Hwang W, Sarkar M, Lewis JD. Chronic statin therapy and the risk of colorectal cancer. Pharmacoepidemiol Drug Saf. 2008;17:869-76.
37. Yood MU, Campbell UB, Rothman KJ, Jick SS, Lang J, Wells KE, et al. Using prescription claims data for drugs available over-the-counter (OTC). Pharmacoepidemiol Drug Saf. 2007;16(9):961-8.